Komori Motoki, Benesch Vidal Maria Luisa, Imai Kenta, Tominaga Yuji, Shibagaki Keisuke, Kutsuzawa Rieko, Kawai Shota, Hayashi Kentaro, Kurosaki Kenichi, Ohuchi Hideo, Toda Kouichi, Saiki Yoshikatsu, Sinning Christoph, Iwai Shigemitsu
Department of Paediatric Cardiovascular Surgery, National Cerebral and Cardiovascular Centre, Osaka, Japan.
Department of Cardiology, University Heart and Vascular Centre Hamburg, Hamburg, Germany.
Cardiovasc Diagn Ther. 2025 Apr 30;15(2):500-508. doi: 10.21037/cdt-24-334. Epub 2025 Apr 17.
Congenitally corrected transposition of the great arteries (ccTGA) remains a rare congenital disorder with a wide range of manifestations. The management of heart failure (HF) of the systemic right ventricle (RV), arrhythmias, heart block, and acquired cardiac conditions require a complex and multi-faceted approach. The objective of this manuscript is to present the current evidence regarding diagnostic, treatment, and management strategies for HF in ccTGA, including ventricular assist device (VAD) therapy and heart transplantation.
A systematic review of the literature was conducted using PubMed, covering the period between 2010 and 2024. The search terms included "heart failure", "ccTGA", "VAD", "heart transplantation", and "systemic RV failure". Two clinical cases were included for illustrative purposes.
HF is a common occurrence in the context of ccTGA, primarily driven by progressive pressure and volume overload of the systemic RV, regurgitation of the systemic atrio-ventricular (AV) valve, and the development of arrhythmias, including complete heart block and (supra-)ventricular tachycardia. The use of HF medication is indicated for symptomatic patients, however, data on the efficacy of standardized HF medication remains limited. Timing of AV-valve replacement is essential to prevent further progression of HF.
In ccTGA, the timing of surgery and interventional treatment approaches, the effect of pharmacological treatment in the context of HF, as well as the timing of initiation of a mechanical circulatory support, VAD and heart transplantation, are based on individualised consensus-level decisions. Optimal management remains a topic of debate due to the scarcity of outcome data. Future investigations should focus on identifying surrogate parameters for guiding treatment.
先天性矫正型大动脉转位(ccTGA)仍然是一种罕见的先天性疾病,表现形式多样。对于系统性右心室(RV)心力衰竭(HF)、心律失常、心脏传导阻滞以及获得性心脏疾病的管理需要采取复杂且多方面的方法。本手稿的目的是介绍有关ccTGA中HF的诊断、治疗和管理策略的当前证据,包括心室辅助装置(VAD)治疗和心脏移植。
使用PubMed对2010年至2024年期间的文献进行系统综述。检索词包括“心力衰竭”、“ccTGA”、“VAD”、“心脏移植”和“系统性RV衰竭”。纳入两个临床病例以作说明之用。
HF在ccTGA中很常见,主要由系统性RV的渐进性压力和容量超负荷、系统性房室(AV)瓣反流以及心律失常的发生所驱动,包括完全性心脏传导阻滞和(室上性)室性心动过速。有症状的患者需要使用HF药物,然而,关于标准化HF药物疗效的数据仍然有限。AV瓣置换的时机对于防止HF的进一步进展至关重要。
在ccTGA中,手术和介入治疗方法的时机、HF背景下药理学治疗的效果以及机械循环支持、VAD和心脏移植开始的时机,均基于个体化的共识水平决策。由于结局数据稀缺,最佳管理仍然是一个有争议的话题。未来的研究应侧重于确定指导治疗的替代参数。